Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057626 · ClinicalTrials.gov registry record
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
A clinical trial of Recurrent Neuroblastoma and Stage 4 Neuroblastoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- 376
- Enrollment target
- 20
- Study locations
NCT03057626 is a study of Recurrent Neuroblastoma and Stage 4 Neuroblastoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 376 participants, below the 1,098-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03057626, a study of Recurrent Neuroblastoma and Stage 4 Neuroblastoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- 376 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research trial studies late effects after treatment in patients with previously diagnosed high-risk neuroblastoma. Studying late effects after treatment may help to decide which treatments for high-risk neuroblastoma are better tolerated with less side effects over time.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Study Locations (20)
California
- Kaiser Permanente Downey Medical Center - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Children's Hospital Los Angeles - Los Angeles
- UCSF Benioff Children's Hospital Oakland - Oakland
- Kaiser Permanente-Oakland - Oakland
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- UCSF Medical Center-Mission Bay - San Francisco
Florida
- Broward Health Medical Center - Fort Lauderdale
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- University of Florida Health Science Center - Gainesville - Gainesville
- Nemours Children's Clinic-Jacksonville - Jacksonville
- AdventHealth Orlando - Orlando
Connecticut
- Connecticut Children's Medical Center - Hartford
- Yale University - New Haven
Alabama
- Children's Hospital of Alabama - Birmingham
Arizona
- Phoenix Childrens Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Alfred I duPont Hospital for Children - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2026-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03057626
The ClinicalTrials.gov registry entry for NCT03057626 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,098-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (66% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03057626 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03057626 about?
NCT03057626 is a clinical study titled "Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma". This research trial studies late effects after treatment in patients with previously diagnosed high-risk neuroblastoma. Studying late effects after treatment may help to decide which treatments for high-risk neuroblastoma are better tolerated with less side effects over time.
What is the current status of trial NCT03057626?
This trial is currently active not recruiting. The enrollment target is 376 participants. The study started on 2017-06-05. Estimated completion is 2026-09-30.
What conditions does trial NCT03057626 study?
This clinical trial studies the following conditions: Recurrent Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma.
What interventions are being tested in trial NCT03057626?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT03057626?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03057626 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RECRUITING · Phase 1
-
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
COMPLETED · Phase 2
-
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.